Treatment of Lymphangitis Carcinomatosis in Metastatic Colon Cancer

Initial Molecular Testing and Stratification

The American Society of Clinical Oncology recommends comprehensive molecular profiling to guide therapy selection, including MSI/MMR status, RAS mutational status, BRAF V600E mutation, and primary tumor sidedness, to determine eligibility for immunotherapy, anti-EGFR therapy, and targeted BRAF/EGFR inhibitor combinations 1, 3, 4
Molecular testing is critical for determining immunotherapy eligibility, with MSI/MMR status being a key factor, according to the National Comprehensive Cancer Network 1, 3, 4
RAS mutational status determines anti-EGFR therapy eligibility, with RAS wild-type patients being eligible for anti-EGFR therapy, as recommended by the European Society for Medical Oncology 1, 2
BRAF V600E mutation identifies candidates for targeted BRAF/EGFR inhibitor combinations, according to the American Society of Clinical Oncology 1
Primary tumor sidedness influences targeted therapy selection in RAS wild-type disease, with left-sided tumors being more likely to benefit from anti-EGFR therapy, as recommended by the European Society for Medical Oncology 2, 3

For MSI-H/dMMR tumors, pembrolizumab immunotherapy is the recommended first-line treatment, providing superior outcomes compared to chemotherapy, according to the National Comprehensive Cancer Network 1, 3, 4
For MSS/pMMR tumors, treatment selection depends on RAS status and tumor sidedness, with chemotherapy combined with anti-EGFR antibodies or bevacizumab being recommended, as per the European Society for Medical Oncology 1, 2, 3
Chemotherapy combined with anti-EGFR antibodies is recommended for RAS wild-type, left-sided primary tumors, demonstrating superior overall survival compared to bevacizumab, according to the American Society of Clinical Oncology 1, 2, 3
Chemotherapy combined with bevacizumab is recommended for RAS wild-type, right-sided primary tumors, providing superior overall survival, as recommended by the European Society for Medical Oncology 1, 2, 3
Chemotherapy combined with bevacizumab is the standard approach for RAS mutant tumors, as anti-EGFR therapy is ineffective in RAS-mutant disease, according to the National Comprehensive Cancer Network 1, 2

FOLFOX or FOLFIRI are standard doublet regimens, with FOLFOXIRI triplet therapy combined with bevacizumab being considered for patients requiring high response rates, as recommended by the American Society of Clinical Oncology 1, 5, 6
Standard 5-FU-based chemotherapy of low toxicity is appropriate for patients with performance status 0-2, according to the European Society for Medical Oncology 5, 6
Capecitabine can substitute for infusional 5-FU in combination regimens, with comparable efficacy, as per the National Comprehensive Cancer Network 5

Early initiation of systemic therapy before symptom development improves outcomes, according to the European Society for Medical Oncology 5, 6
Performance status 0-2 patients should receive full-dose combination therapy, as recommended by the American Society of Clinical Oncology 5, 6

Evaluate treatment efficacy after 2-3 months of therapy, continuing effective therapy and discontinuing chemotherapy in the face of progressive disease, as per the National Comprehensive Cancer Network 5, 6
Second-line chemotherapy using a different protocol is recommended after progression, according to the European Society for Medical Oncology 5, 6
For BRAF V600E-mutant disease after first-line progression, encorafenib plus cetuximab is recommended, as recommended by the American Society of Clinical Oncology 1

Do not use anti-EGFR therapy in RAS-mutant patients, as it provides no benefit and adds toxicity, according to the National Comprehensive Cancer Network 1, 2
Do not combine two targeted agents, as it increases toxicity without survival benefit, as per the European Society for Medical Oncology 8
Do not delay molecular testing, as results are essential for optimal first-line therapy selection, according to the American Society of Clinical Oncology 1
Do not use single-agent 5-FU when combination therapy is tolerable, as combination regimens significantly improve survival, as recommended by the National Comprehensive Cancer Network 5
Bevacizumab must be discontinued at least 6 weeks before any planned surgery due to impaired wound healing, according to the European Society for Medical Oncology 8